Read by QxMD icon Read

Bioidentical hormone therapy

Julia A Files, Lisa N Kransdorf, Marcia Ko, Juliana M Kling, Paru S David, Sandhya Pruthi, Richa Sood, Douglas Creedon, Yu-Hui H Chang, Anita P Mayer
OBJECTIVES: Bioidentical hormone therapy (BHT) is available in the United States in formulations that have been approved by the Food and Drug Administration (FDA) but also in formulations that have not been so approved. The aim of this study was to evaluate the knowledge, beliefs, and prescribing practices of BHT among healthcare providers. STUDY DESIGN: A cross-sectional self-selected responder survey was conducted of health care providers attending primary care Continuing Medical Education (CME) conferences in the United States from May 2012 to April 2013...
December 2016: Maturitas
Ana Marcia I S Gaudard, Sulani Silva de Souza, Maria E S Puga, Jane Marjoribanks, Edina M K da Silva, Maria R Torloni
BACKGROUND: Various hormone therapies (HT) are available to treat menopausal vasomotor symptoms. Bioidentical hormones are chemically identical to those produced by the human body, and several types are well-tested and available on prescription. Many women have opted for bioidentical hormone therapy (BHT) on the assumption that it is safer than other forms of HT. We evaluated the evidence. OBJECTIVES: To determine the effectiveness and safety of bioidentical hormones compared to placebo or non-bioidentical hormones for the relief of vasomotor symptoms...
August 1, 2016: Cochrane Database of Systematic Reviews
P Stute, J Neulen, L Wildt
Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. International guidelines on menopausal hormone therapy (MHT) do not specify on progestogen type, dosage, route of application and duration of safe use. At the same time, the debate on bioidentical hormones including micronized progesterone increases. Based on a systematic literature review on micronized progesterone for endometrial protection, an international expert panel's recommendations on MHT containing micronized progesterone are as follows: (1) oral micronized progesterone provides endometrial protection if applied sequentially for 12-14 days/month at 200 mg/day for up to 5 years; (2) vaginal micronized progesterone may provide endometrial protection if applied sequentially for at least 10 days/month at 4% (45 mg/day) or every other day at 100 mg/day for up to 3-5 years (off-label use); (3) transdermal micronized progesterone does not provide endometrial protection...
August 2016: Climacteric: the Journal of the International Menopause Society
Nanette Santoro, Glenn D Braunstein, Cherie L Butts, Kathryn A Martin, Michael McDermott, JoAnn V Pinkerton
This Scientific Statement finds that there is no rationale for routine prescribing of unregulated, untested, and potentially harmful custom compounded bioidentical hormone therapies.
April 2016: Journal of Clinical Endocrinology and Metabolism
Louiza S Velentzis, Emily Banks, Freddy Sitas, Usha Salagame, Eng Hooi Tan, Karen Canfell
Menopausal Hormone Therapy (MHT) use in Australia fell by 55% from 2001 to 2005, following the release of large-scale findings on its risks and benefits. Comprehensive national data, including information on overall prevalence of MHT use as well as information on duration of use in Australia have not been reported since the 2004-5 National Health Survey, when 11% of women aged 45+ years were estimated to be current MHT users. No national data are available on prevalence of use of "bioidentical" hormone therapy (BHT)...
2016: PloS One
Joao Correia De Pinho, Lusine Aghajanova, Christopher N Herndon
BACKGROUND: Gynecomastia is a disorder of the endocrine system characterized by an abnormal presence of a palpable unilateral or bilateral enlargement and proliferation of glandular ductal benign breast tissue in male individuals. This case discusses the medical implications of an unregulated, indirect exposure to nonformulary, bioidentical hormone replacement therapy in male children. CASE: An 8-year-old boy presented with prepubertal gynecomastia secondary to estrogen exposure from maternal use of bioidentical hormonal replacement therapy (the Wiley protocol)...
January 2016: Journal of Reproductive Medicine
Marcie K Richardson
No abstract text is available yet for this article.
April 2016: Menopause: the Journal of the North American Menopause Society
Meghan Hewlett, Shruthi Mahalingaiah
PURPOSE OF REVIEW: Despite an incidence of 1% among women under the age of 40, primary ovarian insufficiency (POI) is still poorly understood. As the variable cause and presentation of POI complicate its management, a standard regimen for treatment remains to be established. However, emerging research has provided new insight on current mainstays of treatment as well as novel management approaches and therapeutic interventions. RECENT FINDINGS: Recent clinical trials in women with POI indicate that the widely used regimen of transdermal estradiol and medroxyprogesterone acetate restores bone mineral density to a level equal to women with normal ovarian function...
December 2015: Current Opinion in Endocrinology, Diabetes, and Obesity
JoAnn V Pinkerton, James H Pickar
OBJECTIVE: We review the historical regulation of drug compounding, concerns about widespread use of non-Food and Drug Admiistration (FDA)-approved compounded bioidentical hormone therapies (CBHTs), which do not have proper labeling and warnings, and anticipated impact of the 2013 Drug Quality and Security Act (DQSA) on compounding. METHODS: US government websites were searched for documents concerning drug compounding regulation and oversight from 1938 (passage of Federal Food, Drug, and Cosmetic Act [FDCA]) through 2014, including chronologies, Congressional testimony, FDA guidelines and enforcements, and reports...
February 2016: Menopause: the Journal of the North American Menopause Society
James V Hennessey
OBJECTIVE: To describe the history, refinements, implementation, physiology, and clinical outcomes achieved over the past several centuries of thyroid hormone replacement strategies. METHODS: A Medline search was initiated using the following search terms: bioidentical thyroid hormone, thyroid hormone extract, combination thyroxine (T4) and tri-iodothyronine (T3) therapy, homeopathic thyroid hormone therapy, and thyroid hormone replacement. Pertinent articles of interest were identified by title (and where available abstract) for further review...
October 2015: Endocrine Practice
Marlene Chism
Patients who choose elective procedures such as laser treatments, plastic surgery, Botox, fillers, bioidentical hormone therapy, or alternative medicine will leave your practice if their experience is anything less than favorable. This is true even if they get the results they were seeking. It is up to the office manager to create the right environment and engagement from the staff to ensure sustainability. This article offers seven reasons practices lose patients to the competition, and what to do to course-correct...
March 2015: Journal of Medical Practice Management: MPM
Andrew M Kaunitz, Jonathan D Kaunitz
No abstract text is available yet for this article.
September 2015: Menopause: the Journal of the North American Menopause Society
Vrabic L Dezman, M Z Gersak, K Gersak
No abstract text is available yet for this article.
May 2015: International Journal of Gynecological Cancer
Sebastian Mirkin, Julia M Amadio, Brian A Bernick, James H Pickar, David F Archer
Several formulations combining estrogens and progestins for hormone therapy (HT) have been approved worldwide for the treatment of menopausal symptoms, yet recent data indicate a decline in their use and an increase in compounded bioidentical HT. Up to now, no single product combining natural 17β-estradiol and progesterone has been approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). A phase 3 trial (REPLENISH) is underway to study a novel oral formulation of solubilized 17β-estradiol and natural progesterone combined in a single gelatin capsule (TX-001HR; TherapeuticsMD, Inc, Boca Raton, FL) for treating vasomotor symptoms (VMS) in postmenopausal women...
May 2015: Maturitas
Jennifer R Fishman, Michael A Flatt, Richard A Settersten
In 2002, the Women's Health Initiative, a large-scale study of the safety of hormone replacement therapy (HRT) for women conducted in the United States, released results suggesting that use of postmenopausal HRT increased women's risks of stroke and breast cancer. In the years that followed, as rates of HRT prescription fell, another hormonal therapy rose in its wake: bioidentical hormone replacement therapy (BHRT). Anti-aging clinicians, the primary prescribers of BHRT, tout it as a safe and effective alternative to treat menopausal symptoms and, moreover, as a preventative therapy for age-related diseases and ailments...
May 2015: Social Science & Medicine
JoAnn V Pinkerton, Nanette Santoro
OBJECTIVE: Two surveys (Harris and Rose surveys) were conducted to quantify the use of compounded hormone therapy (CHT; or bioidentical hormone therapy) among perimenopausal and postmenopausal women in the United States, to assess women's knowledge of CHT versus Food and Drug Administration (FDA)-approved hormone therapy, and to gather information on menopausal experience. METHODS: The Harris survey was administered to 801 women aged 45 to 60 years who had experienced at least one menopausal symptom...
September 2015: Menopause: the Journal of the North American Menopause Society
Sinan Guven, Jennifer S Lindsey, Ishwari Poudel, Sireesha Chinthala, Michael D Nickerson, Behzad Gerami-Naini, Umut A Gurkan, Raymond M Anchan, Utkan Demirci
Hormone replacement therapies have become important for treating diseases such as premature ovarian failure or menopausal complications. The clinical use of bioidentical hormones might significantly reduce some of the potential risks reportedly associated with the use of synthetic hormones. In the present study, we demonstrate the utility and advantage of a microfluidic chip culture system to enhance the development of personalized, on-demand, treatment modules using embryoid bodies (EBs). Functional EBs cultured on microfluidic chips represent a platform for personalized, patient-specific treatment cassettes that can be cryopreserved until required for treatment...
March 2015: Stem Cells Translational Medicine
JoAnn V Pinkerton
Unsubstantiated claims, lack of scientific safety and efficacy data, and lack of quality control surround custom-compounded bioidentical hormone products. FDA-approved hormone therapy provides tested and regulated therapy without the risks of unregulated and untested custom preparations.
December 2014: Menopause: the Journal of the North American Menopause Society
Franco Guidozzi, A Alperstein, J S Bagratee, P Dalmeyer, M Davey, T J de Villiers, S Hirschowitz, T Kopenhager, S P Moodley, P Roos, A Shaw, O Shimange, T Smith, C Thomas, J Titus, Z van der Spuy, J van Waart
The South African Menopause Society (SAMS) consensus position statement on menopausal hormone therapy (HT) 2014 is a revision of the SAMS Council consensus statement on menopausal HT published in the SAMJ in May 2007. Information presented in the previous statement has been re-evaluated and new evidence has been incorporated. While the recommendations pertaining to HT remain similar to those in the previous statement, the 2014 revision includes a wider range of clinical benefits for HT, the inclusion of non-hormonal alternatives such as selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors for the management of vasomotor symptoms, and an appraisal of bioidentical hormones and complementary medicines used for treatment of menopausal symptoms...
June 19, 2014: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
Hannelore Rott
Many large trials in the past 15 years have proven an increased risk of vascular complications in women using oral, mostly non-bioidentical, hormone therapy. The risk of vascular complications depends on the route of administration (oral versus transdermal), age, duration of administration, and type of hormones (bioidentical versus non-bioidentical). Acquired and/or hereditary thrombophilias (eg, factor V Leiden, prothrombin mutation G20210A, and others) lead to a further increase of risk for venous thromboembolism, stroke, or myocardial infarction...
2014: International Journal of General Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"